Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anthrax
AVANIR Pharmaceuticals Licenses Anthrax Monoclonal Antibody Program to Emergent BioSolutions
March 21st, 2008
AVANIR Pharmaceuticals (NASDAQ:AVNR) announced that it has executed a definitive agreement to sell its portfolio of human monoclonal anthrax antibodies to Emergent BioSolutions (NYSE:EBS). As part of the transaction, Emergent acquired AVANIR's lead candidate (AVP-21D9) along with several additional anthrax antibodies. In addition, Emergent also received a limited exclusive license to use AVANIR's proprietary Xenerex(TM) Technology platform to develop future human monoclonal antibodies targeted against Bacillus anthracis. Under terms of the definitive agreement, AVANIR has the potential to receive up to $1.75 million in upfront and milestone payments, as well as royalties on annual net...
Source: Health Business Week (2008-03-21)
|
|
Advertisement |
|
|
|
